PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time.
加利福尼亚州圣荷西,2024年11月26日(环球新闻)-- PROCEPt 机器人公司(纳斯达克:PRCT)("公司"),是一家专注于通过开发变革性泌尿外科解决方案来推进患者护理的外科机器人公司,今天宣布管理层成员将在即将举行的第36届派杰投资医疗会议上发表演讲,会议将在纽约市举行。管理层计划于东部时间12月4日星期三上午8:30进行演讲。
A live webcast of each event, as well as an archived recording, will be available on the "Investors" section of the company's website at: . The webcasts will be archived and available for replay for at least 90 days after the event.
每个活动的现场直播,以及录制的存档,将在公司网站的“投资者”部分可用。网络直播将被存档,并在活动结束后至少可回放90天。
About PROCEPT BioRobotics Corporation
关于PROCEPt 机器人公司
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
PROCEPt 机器人公司是一家专注于通过开发变革性泌尿外科解决方案来推进患者护理的外科机器人公司。HYDROS机器人系统是唯一一种人工智能驱动的机器人科技,能够提供水刀治疗。PROCEPt 机器人公司设计水刀治疗以为男性提供有效、安全和持久的治疗结果,适用于因良性前列腺增生(BPH)引起下尿路症状(LUTS)的患者,这与前列腺的大小和形状或外科医生的经验无关。良性前列腺增生是最常见的前列腺疾病,影响美国大约4000万男性。公司已经开发出一份重要且日益增长的临床证据,拥有超过150篇经过同行评审的出版物,支持水刀治疗的好处和临床优势。
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
投资者联系人:
马特·巴克索
副总裁,投资者关系和业务运营
m.bacso@procept-biorobotics.com